[Recommendations for the treatment of bancroftian filariasis in symptomless and diseased patients].
The goals of treatment for lymphatic filariasis are: to prevent, reverse, or halt progression of disease; and to interrupt transmission of the parasite. Selecting the appropriate therapy for the patient with lymphatic filariasis requires knowledge of the various clinical features of filarial disease and their pathogenesis. In the past, treatment of lymphatic filariasis has focused primarily on antiparasitic chemotherapy; however, for many of the acute and chronic manifestations of lymphatic filariasis, it is now clear that supportive or other forms of clinical care are even more important than antiparasitic medication in order to prevent worsening of the disease. Regardless of the clinical manifestations of filarial disease in a particular patient, the following three components of treatment should, in general, be considered: supportive or disease specific clinical care (including hygiene and diet), patient education and counseling and finally, antiparasitic chemotherapy with diethylcarbamazine (DEC) and/or the combination of DEC with ivermectin. The authors also describe the proportional efficacy of diethylcarbamazine and ivermectin, alone or in combination, for use in mass treatment aiming at transmission interruption and the use of hygiene as a public health approach for lymphedema prevention.
Dreyer
Gerusa
G
Centro de Pesquisas Aggeu Magalhães, Fundação Oswaldo Cruz, Recife, Brasil.
Dreyer
Patrícia
P
Noroes
Joaquim
J
D000818:Animals; D004605:Elephantiasis, Filarial / Q000628:therapy*; D006801:Humans; D014958:Wuchereria bancrofti